HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russia
Recruiting · NCT06127290 · Observational (researchers observe without assigning treatment) · Lead sponsor: Euresist Network GEIE
View the official record on ClinicalTrials.gov →What this trial is about
Cohort based prospective monitoring of the spread of HIV drug resistance during a phase when new anti-HIV drugs are introduced.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- naïve patients starting 2nd generation INSTI treatment
- first line patients under 2nd generation INSTI treatment with either viral RNA sequence before therapy start, or PBMC available with PBMC sample date not more than 3 years from therapy start date (with reasonably sure history of no failure in the interval from therapy start date to PBMC sample date\]).
Exclusion criteria
- patients not having a signed informed consent for the EIDB data repository, if required by local/national legislation in order to have data in the common data repository.
- patients not having Signed Informed consent for the present study, if required by local authorities iii) Persons aged \< 18 at baseline
Where it is running
4 locations listed.
- University Hospital of Cologne - Cologne, Germany
- University Hospital of Siena - Siena, Italy
- Karolinska Institutet - Stockholm, Sweden
- Pomeranian Medical University Szczecin - Szczecin, Poland